Clinical Trials Browser

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

Phase 2 Completed

104 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03015129 2024-02-06

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Phase 2 Completed

80 enrolled 9 charts

Gynecologic

Recurrence, Endometrial Neoplasms

NCT02807454 2023-02-21

FUSIONMM-003

Phase 2 Terminated

37 enrolled 21 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Phase 1/2 Completed

35 enrolled 25 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04015739 2022-08-17

BOLD

Phase 2 Unknown

74 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Recurrence

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02207530 2020-09-29

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

112 enrolled 20 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

267 enrolled 27 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02221960 2019-03-13

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Phase 1 Completed

39 enrolled

Recurrence

NCT03000452 2018-10-16

FUSION-MM-005

Phase 2 Completed

18 enrolled 16 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

AB02

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

FRAIL-IMMUNE

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

FUSIONMM-003

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

BOLD

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

EAGLE

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

FUSION-MM-005